Publications

Tissue sections showing advanced prostate cancer stained with hematoxylin and eosin (left) or an antibody targeting CEACAM5 (right)
Tissue sections showing advanced prostate cancer stained with hematoxylin and eosin (left) or an antibody targeting CEACAM5 (right) Credit: Lee Lab

2019 | 2018 | 2017 | 2016 | 2014 | 2013 | 2012

2019

Shapovalova M, Lee JK, Li Y, Vander Griend DJ, Coleman I, Nelson PS, Dehm SM, LeBeau AM. PEG10 promoter-driven expression of reporter genes enables molecular imaging of lethal prostate cancer. Cancer Res. 2019 Sep 17.

Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, Small EJ, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019 Jul 30. 

Lee JK and Priceman SJ. Precision Medicine-Enabled Cancer Immunotherapy. Cancer Treat Res. 2019;178:189-205.

Winters BR, De Sarkar N, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL, Lam HM, Hsieh AC. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. JCI Insight. 2019 May 30;5. 

2018

Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, Smith BA, Cheng C, Tsai BL, Cheng D, Huang J, Kurdistani SK, Graeber TG, Witte ON. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018 Oct 5;362(6410):91-95.

Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4473-E4482.

2017

Park JW, Lee JK, Witte ON, Huang J. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod Pathol. 2017 Sep;30(9):1262-1272.

2016

Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016 Apr 11;29(4):536-547.

Park JW, Lee JK, Phillips JW, Huang P, Cheng D, Huang J, Witte ON. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4482-7.

Drake JM*, Paull EO*, Graham NA, Lee JK, Smith BA, Titz B, Stoyanova T, Faltermeier CM, Uzunangelov V, Carlin DE, Fleming DT, Wong CK, Newton Y, Sudha S, Vashisht AA, Huang J, Wohlschlegel JA, Graeber TG, Witte ON, Stuart JM. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell. 2016 Aug 11;166(4):1041-1054.

Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6457-E6466. 

2014

Drake JM, Lee JK, Witte ON. Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer. Mol Cell Biol. 2014 May;34(10):1722-32.

2013

Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):E4762-9.

2012

Lee JK and Schiller G. Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Adv Hematol Oncol. 2012 Jan;10(1):60-2.